Current Report Filing (8-k)
April 12 2021 - 06:16AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
April 7, 2021
Date of Report (Date of earliest event reported)
ELITE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Nevada |
|
001-15697 |
|
22-3542636 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
165 Ludlow Avenue, Northvale, New Jersey 07647
(Address of principal executive offices)
(201) 750-2646
(Registrant’s telephone number, including area code)
|
(Former name or former address, if changed since
last report.) |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth
company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If
an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each
class |
|
Trading Symbol(s) |
|
Name of each exchange on which
registered |
|
|
|
|
|
|
Item 5.02 |
Departure
of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers. |
On April 7, 2021, Carter J. Ward notified Elite Pharmaceuticals,
Inc. (the “Company”) of his intent to leave the Company and resign
from his position as Chief Financial Officer, Treasurer and
Secretary to pursue another opportunity. Mr. Ward’s last day with
the Company will be May 14, 2021.
In addition to the titles discussed above, Mr. Ward is the
Company’s Principal Financial Officer and Principal Accounting
Officer. The Company has commenced a search for Mr. Ward’s
replacement.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, as amended, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly
authorized.
|
|
|
|
|
ELITE PHARMACEUTICALS,
INC. |
|
(Registrant) |
|
|
|
|
|
|
Dated: April 12,
2021 |
By: |
/s/ Nasrat Hakim |
|
|
Name: Nasrat Hakim
Title: President and CEO
|
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Apr 2022 to May 2022
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From May 2021 to May 2022